# **Profile and Risk Factor of Hepatocellular Carcinoma Patients**

Siti Hasnita O. Purba<sup>1</sup>, Imelda Rey<sup>2, 3</sup>

<sup>1</sup> Student of Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
<sup>2</sup> Division of Gastroenterohepatology, Internal Medicine Department, Universitas Sumatera Utara, Medan, Indonesia
<sup>3</sup> Adam Malik General Hospital, Bunga Lau Street, Medan, Indonesia

Keywords: Hepatocellular Carcinoma, Profile, Risk Factors.

Hepatocellular carcinoma (HCC) is the most common primary liver malignant tumor in the world. The Abstract: incidence of hepatocellular carcinoma varies worldwide and is correlated with the incidence of hepatitis B virus and hepatitis C virus. In addition to viral hepatitis, there are other risk factors such as alcohol consumption that causes alcoholic liver disease and obesity and diabetes associated with non-alcoholic fatty liver disease (NAFLD) / non-alcoholic steatohepatitis (NASH). Most of these risk factors lead to the development of liver cirrhosis. One of the most commonly used stages of hepatocellular carcinoma is Barcelona Clinic Liver Cancer (BCLC) staging system that can also determine which therapy will be given to patients with hepatocellular carcinoma. The aim of this study was to determine the profile and risk factors of hepatocellular carcinoma patients. This cross-sectional study using HCC patient's medical records in Adam Malik General Hospital from January 2016 - June 2017. There were 182 patients with hepatocellular carcinoma with the highest age group 40-60 years (54.4%), dominated by male sex (80.2%), occupation with the highest prevalence is self-employed (27.5%), has no family history (97.8%), risk factors with the highest prevalence is hepatitis B (47.3%), Child-Pugh B (57.1%), multinodular radiology (51.1%), AFP increased, BCLC stage B (40.7%) and treated with symptomatic treatment (78%). The highest risk factor in patients with hepatocellular carcinoma is hepatitis B.

SCIENCE AND TECHNOLOGY PUBLICATIONS

## **1** INTRODUCTION

Hepatocellular carcinoma (HCC) is a primary malignant liver tumor that originating from hepatocytes (Budihusodo, 2014). HCC is the ninth most common cancer in women and fifth in men. HCC mortality rate is also very high, in second place of cancer-related death after lung cancer (GLOBOCAN 2012).

The incidence of HCC varies worldwide and correlates with regional prevalence of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) (Budihusodo, 2014). In the endemic areas, HBV is majority obtained by vertical and perinatal transmission more than 90% of these cases changes to chronic HBV carriers. HBV is a well-known cause of HCC because it can become HCC without cirrhosis, although most HBV (70-90%) develop into cirrhosis prior to becoming HCC (Yang et al, 2011). Some cases of HCV has been reported, in Italy 44-66% turn in to HCC cases and about 80% in Japan. Whereas, in United States, the chronic HCV was also a major risk factor for HCC (El-Serag, 2007).

Other risk factors of viral hepatitis, such as alcohol consumption that associated to alcoholic liver disease and obesity and diabetes associated with non-alcoholic fatty liver disease (NAFLD) / non-alcoholic steatohepatitis (NASH). Most of these risk factors lead to the development of liver cirrhosis present in 80-90% of HCC patients (El-Serag, 2011). Several studies reported that risk of developing HCC through NASH-associated cirrhosis is lower than other liver diseases, such as HCV and HBV (Takuma, 2010).

Although the prevalence of HCC in patients with NASH is low, but the prevalence of obesity-related NASH in the United States is high and it is a leading to indicated a major causes for liver transplantation (Wong, 2014).

Purba, S. and Rey, I.

Profile and Risk Factor of Hepatocellular Carcinoma Patients DOI: 10.5220/0010070204250428

ISBN: 978-989-758-449-7

Copyright © 2020 by SCITEPRESS - Science and Technology Publications, Lda. All rights reserved

In Proceedings of the International Conference of Science, Technology, Engineering, Environmental and Ramification Researches (ICOSTEERR 2018) - Research in Industry 4.0, pages 425-428

# 2 METHODS

This study was a cross-sectional study design. Data were taken by using secondary data from medical record of hepatocellular carcinoma patients at RSUP Haji Adam Malik Medan period 1<sup>st</sup> of January 2016 until 30<sup>th</sup> of June 2017. The sampling method was done by total sampling method. Data taken include age, sex, risk factors, laboratory results, child-pugh classification, radiological results, BCLC stage, tumor marker results and therapy provided.

## **3 RESULT**

This study was obtained 182 patients hepatocellular carcinoma who visited the RSUP Haji Adam Malik Medan during the period 01 January 2016 - 30 June 2017.

Table 1 : Characteristics of HCC patients

Characteristic	n = 182
Sex	
Men	146 (80,2)
Women	36 (19,8)
Age (years)	
< 40	25 (13,7)
40-60	99 (54,4)
> 60	58 (31,9)
0	
Occupation	10 (0.0)
Government	18 (9,9)
employees	19 (10,4)
Private employees	50 (27,5)
Entrepreneur	39 (21,4)
Farmers	17 (9,3)
Housewife	17 (9,3)
Retired	22 (12,1)
Others	
Risk factors	
HBV	86 (47,3)
HCV	10 (5,5)
Cirrhosis	60 (33)
Alcohol	41 (22,5)
Diabetes	16 (8,8)
Obesity	29 (15,9)
Laboratory data	
Hb (g/dL)	10,9±2,7
Leucocyte	10.705,13±4957,31

(cells/mm <sup>3</sup> )	275.756,90±1,60
Trombosite	69,81±76,09
(thousand/mm <sup>3</sup> )	201,65±252,12
ALT (U/L)	277,18±265,64
ASP (U/L)	$345,88{\pm}305,02$
ALP (U/L)	3,8±6,4
Gamma-GT (U/L)	$2,7\pm0,65$
Bilirubin (mg/dL)	$1,2\pm0,39$
Albumin (g/dL)	
INR	
Tumor marker	
AFP (ng/ml)	26.728,84±1,67
CEA (ng/ml)	464,33±1856,02
CA125 (u/ml)	286,26±261,67
CA19-9 (u/ml)	161,09±351,64
Child-Pugh score (%)	
А	47 (25,8)
В	104 (57,1)
C	27 (14,8)
Missing	4 (2,2)
Tumor type (%)	
Soliter	52 (28,6)
Multinoduler	93(51,1)
Diffuse	7 (3,8)
Missing	30 (16,5)
BCLC stage (%)	
	14(7.7)
C <sup>0</sup> GY PUB	14 (7,7) 30 (16,5)
B	74 (40,7)
C	13 (7,1)
D	25 (13,7)
Missing	26 (14,3)
Missing	20 (14,5)
Treatment (%)	
Hepatic resection	2 (1,1)
ТАСЕ	37 (20,3)
Liver transplantation	142 (78)
Symptomatic	1 (0,5)
5 <u>F</u>	- (-,-)

## 4 DISCUSSION

Table 1 shows the characteristics of patients in which the largest number of hepatocellular carcinoma patients were men. This is in accordance with previous study that found the most sex in hepatocellular carcinoma patients were male (Karageorgos et al, 2017; Mittal et al, 2015). Sex influences are also associated to sex hormones namely androgens and estrogens which is main regulated the progression of HBV infection and the incidence of HBV-associated to hepatocellular carcinoma, in which androgens increase the transcription and replication of the HBV gene whereas the estrogen plays a protective role by decreasing the transcription of HBV RNA and the number of inflammatory cytokines (Montella, 2015). In addition, high alcohol consumption in men also increases the hepatocellular carcinoma incidence risk in people that infected by hepatitis B and hepatitis C virus (Budihusodo, 2014).

The most risk factor in hepatocellular carcinoma patients in this study is hepatitis B. Chronic hepatitis B infection was a major risk factor for hepatocellular carcinoma in the world (El-Serag, 2011). About 80% of the world's hepatocellular carcinoma cases are in developing countries such as East Asia and Southeast Asia and Central Africa, which is known to be a high prevalence of viral hepatitis (Budihusodo, 2014).

Chronic hepatitis B can progress to hepatocellular carcinoma without cirrhosis, although most develop into cirrhosis before it becomes hepatocellular carcinoma (Yang et al, 2011). In this study, the second highest risk factor was cirrhosis hepatis. This is associated with high incidence of hepatitis B and other risk factors that can develop into cirrhosis before becoming hepatocellular carcinoma.

The laboratory results of hepatocellular carcinoma patients where the mean Hb decreases, normal leukocytes, normal platelets, ALT increases, ASP increases, ALP increases, Gamma-GT increases, bilirubin increases, normal albumin and normal INR. The most common abnormalities in liver tumors are elevated alkaline phosphatase (ALP) and GT gamma. The concentrations of SGOT / AST and SGPT / ALT enzymes in hepatocellular carcinoma at baseline did not show an increase unless the underlying disease was cirrhosis of the liver. When the tumor gets bigger and greater liver damage can also be found an increase in AST and ALT (Amirudin, 2014).

In the results of tumor marker examination of hepatocellular carcinoma patients found the average AFP increased, the average CEA increased, the average CA125 increased, and the average CA19-9 increased. AFP is a specific tumor marker in diagnosing hepatocellular carcinoma, whereas other tumor markers such as CEA, CA125 and CA19-9 are not specific but may increase with worsening disease (Li et al, 2015). In Asia, hepatocellular carcinomas usually appear as well-described, solitary or multifocal masses and are associated with secondary cirrhosis due to hepatitis B. In western countries, hepatocellular carcinomas usually appear as diffuse infiltration masses and are associated with alcoholinduced cirrhosis (Sharma, 2009). In this study, the most radiology results in patients with hepatocellular carcinoma multinodular. It is accordance with the previous study that get the most tumor type is multinodular (Su et al, 2017).

The most common of Child-Pugh classification in hepatocellular carcinoma patients was Child-Pugh B. This study is in accordance with the previous study which received the most Child-Pugh classification is Child-Pugh B (Nadhim, 2016). The most BCLC staging in patients with hepatocellular carcinoma is stage B. According to previous study, it showed that the highest stage of BCLC in hepatocellular carcinoma hepatitis B virus etiology is stage B (Nadhim, 2016). While in another study received the highest stage BCLC was stage C (Mittal et al, 2015; Hidayat, 2007). BCLC staging is closely related to the Child-Pugh classification and radiology results in patients, where in this study the most Child-Pugh classifications are Child-Pugh B and multinodular radiology results. That all determine the choice of therapy which in this study the most common treatment to the patients with hepatocellular carcinoma is symptomatic treatment.

#### LOGY PUBLIC ATIONS

## 5 CONCLUSION

Most of patients were in BCLC staging B, with the highest risk factor in patients with hepatocellular carcinoma is hepatitis B.

#### ACKNOWLEDGEMENTS

The authors gratefully acknowledge that the present research is supported by Ministry of Research and Technology and Higher Education Republic of Indonesia.

#### REFERENCES

- Amirudin, R. 2014, 'Fisiologi dan Biokimia Hati', in Setiati, S. et al. (eds) *Buku Ajar Ilmu Penyakit Dalam Jilid II*. Interna Publishing. Jakarta, 6<sup>th</sup> Edition.
- Budihusodo, U. 2014, 'Karsinoma Hati', in Setiati, S. et

ICOSTEERR 2018 - International Conference of Science, Technology, Engineering, Environmental and Ramification Researches

al. (eds) *Buku Ajar Ilmu Penyakit Dalam Jilid III*. Interna Publishing. Jakarta, 6<sup>th</sup> Edition.

- El–Serag, H. B., & Rudolph, K. L. 2007. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. *Gastroenterology*, 132(7), 2557-2576.
- El-Serag, H. B. 2011, 'Hepatocellular carcinoma', *The New England Jorunal of Medicine*, 365, pp. 1118– 1127.
- Hidayat, H. 2007. Perbedaan profil klinik karsinoma hepatoseluler yang terinfeksi kronik virus hepatitis B dengan virus hepatitis C (Doctoral dissertation, FacultyofMedicine). Availableat: http://eprints.undip.ac .id/22680/1/Hendri\_Hidayat.pdf
- International Agency of Research on Cancer 2012, *GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worlwide in 2012.* Available at: http://globocan.iarc.fr/Pages/fact\_sheets\_population.as px.
- Karageorgos, S. A., Stratakou, S., Koulentaki, M., Voumvouraki, A., Mantaka, A., Samonakis, D., et al. 2017. Long-term change in incidence and risk factors of cirrhosis and hepatocellular carcinoma in Crete, Greece: a 25-year study. *Annals of* gastroenterology, 30(3), 357.
- Li, Y., Li, D. J., Chen, J., Liu, W., Li, J. W., Jiang, P., et al. 2015. Application of Joint Detection of AFP, CA19-9, CA125 and CEA in Identification and Diagnosis of Cholangiocarcinoma. *Asian pac J Cancer* prev, 16, 3451-3455.
- Mittal, S., Sada, Y. H., El-Serag, H. B., Kanwal, F., Duan, Z., Temple, S., et al. 2015. Temporal trends of nonalcoholic fatty liver disease–related hepatocellular carcinoma in the veteran affairs population. *Clinical Gastroenterology and Hepatology*, 13(3), 594-601.
- Montella, M., D'Arena, G., Crispo, A., Capunzo, M., Nocerino, F., Grimaldi, M., et al. 2015. Role of sex hormones in the development and progression of hepatitis B virus-associated hepatocellular carcinoma. *International journal of endocrinology*, 2015.
- Nadhim, M., Suharti, C., Hardian. 2016. 'Distribusi Geografis dan Tingkat Keparahan Pasien Karsinoma Hepatoseluler Etiologi Virus Hepatiis B di RS Kariadi Semarang', Jurnal Kedokteran Diponegoro, 5(4), pp.1290-1302.
- Sharma, R. and Madhusudhan, K. S. 2009, 'Malignant Focal Lesions of The Liver', in Gupta, A. K., Chowdhury, V., and Khandelwal, N. (eds) *Diagnostic Radiology Gastrointestinal and Hepatobiliary Imaging*. Jaypee. New Delhi, 3<sup>rd</sup> Edition.
- Su, Y. W., Liu, P. H., Hsu, C. Y., Lee, Y. H., Hsia, C. Y., Ho, S. Y., et al. 2017. Prognostic impact of diabetes mellitus on hepatocellular carcinoma: Special emphasis from the BCLC perspective. *PloS* one, 12(3), e0174333.
- Takuma, Y., & Nouso, K. 2010. Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review. *World journal of* gastroenterology: WJG, 16(12), 1436.

- Wong, R. J., Cheung, R., & Ahmed, A. 2014. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the US. *Hepatology*, 59(6), 2188-2195.
- Yang, J. D., Kim, W. R., Coelho, R., Mettler, T. A., Benson, J. T., Sanderson, S. O., et al. 2011. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. *Clinical Gastroenterology* and Hepatology, 9(1), 64-70.

428